SYNTHESIS OF 4-ARYL-1*H*-PYRAZOLES BY SUZUKI-MIYAURA CROSS COUPLING REACTION BETWEEN 4-BROMO-1*H*-1-TRITYL-PYRAZOLE AND ARYLBORONIC ACIDS

Hayato Ichikawa,[1,2] Miho Nishioka,[1] Masao Arimoto,[1] and Yoshihide Usami[1]*

[1]Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki 569-1094, Osaka, Japan; E-mail: usami@gly.oups.ac.jp

[2]College of Industrial Technology, Nihon University, 1-2-1 Izumi-cho, Narashino, Chiba 275-8575, Japan (present address)

Abstract − A general procedure for the synthesis of 4-aryl-1*H*-pyrazoles by the Suzuki-Miyaura cross coupling reaction between 4-bromo-1*H*-1-tritylpyrazole and commercially available arylboronic acids was developed. Using this procedure, a direct synthesis of 4-aryl-1*H*-pyrazoles possessing functional groups, such as hydroxyl, nitro, and amino groups, on the aryl ring was realized. Those molecules could not be prepared by our previous synthesis of 4-aryl-1*H*-pyrazoles via the Kumada cross coupling reaction.

The exploration of new methods for the synthesis of heterocyclic compounds is important work for synthetic organic chemists as most drugs or bioactive compounds possess a heterocyclic part in their molecules. Pyrazoles are one of the most important heterocyclic compounds.[1,2] There are a lot of well-known pyrazole-containing drugs, including celecoxib,[3,4] rimonobant,[5] and 4-methylpyrazole (fomepizole).[6,7] Extensive studies of the synthesis of substituted or functionalized pyrazoles have been carried out.[8,9] However, most of them deal with the construction of a pyrazole ring by the 2+3 cycloaddition of substituted parts.

The discovery of a novel binuclear platinum (II) complex bearing 4-methylpyrazole as the ligand (4mpz), which exhibits enhanced antitumor activity in cisplatin-resistant L1210/R cell lines,[10] has fueled our interest in the direct functionalization of pyrazoles at C-4. Pardo and co-workers reported the synthesis of

4-aryl-1*H*-pyrazoles via the Stille coupling reaction, as illustrated in Scheme 1 (eq. 1).[11] In that procedure, toxic tributyltin chloride was required for the preparation of cross-coupling substrates and the chemical yields were not satisfactory. Another example is the Suzuki coupling (eq. 2) reported by Fu and co-workers.[12] In this case, relatively expensive tricyclopentylpalladium was required as an additive for the reaction and 1-benzyl-4-phenyl-1*H*-pyrazole (**1a'**) was obtained in 64% yield. This approach is closely related to a series of Harrity's synthetic studies on functionalized pyrazoles.[13-16] Meanwhile, we have developed a method for the synthesis of 4-arylpyrazoles via the Kumada coupling with only 0.2 mol% palladium catalyst, as shown in eq. 3.[17] This procedure is quite efficient in that 4-phenyl-1*H*-1-tritylpyrazole (**1a**) was synthesized in 99% yield, but has a drawback in that it is difficult to prepare Grignard reagents at the same time. Then, we attempted to perform an alternative procedure where we synthesized 4-aryl-1*H*-pyrazoles under milder conditions. Herein we describe a simple method for the synthesis of 4-aryl-1*H*-pyrazoles via the Suzuki-Miyaura coupling reaction[18] between 4-bromo-1*H*-1-tritylpyrazole and commercially available arylboronic acids.

Scheme 1. Known methods for direct arylation at C-4 of 1*H*-pyrazoles

Commercially available pyrazole was converted into 4-bromo-1*H*-1-tritylpyrazole (**3**) via **2** using a known method.[11,17] Compound **3** was reacted with several commercially available boronic acids in the presence of 5 mol% palladium acetate, triphenylphosphine, and potassium carbonate under reflux in THF. The results of the Suzuki-Miyaura cross coupling reaction are summarized in Table 1. The reaction with phenylboronic acid resulted in 92% yield of **1a** (entry 1), which is slightly lower than that obtained with

**Scheme 2.** Synthesis of 4-aryl-1*H*-pyrazoles via Suzuki-Miyaura coupling

Table 1. Synthesis of **1** via Suzuki coupling between **3** and arylboronic acids

| entry	reagent	product	yield (%)
1	phenylboronic acid	**1a** : Ar = phenyl	92
2	4-hydroxyphenylboronic acid	**1b** : Ar = 4-hydroxyphenyl	63
3	3-hydroxyphenylboronic acid	**1c** : Ar = 3-hydroxyphenyl	53
4	2-methylphenylboronic acid	**1d** : Ar = 2-methylphenyl	58
5	3-nitrophenylboronic acid	**1e**: Ar = 3-nitrophenyl	35
6	3-aminophenylboronic acid	**1f** : Ar = 3-aminophenyl	41
7[a]	3-aminophenylboronic acid	**1f**: Ar = 3-aminophenyl	36
8	2-thiopheneboronic acid	**1g** : Ar = thiophen-2-yl	57
9[b]	2-thiopheneboronic acid	**1g** : Ar = thiophen-2-yl	99
10	3-thiopheneboronic acid	**1h** : Ar = thiophen-3-yl	50
11	2-furylboronic acid	**1i**: Ar = fur-2-yl	47

a. 10 mol% of palladium catalyst were added.

b. 2.4 Equivalent s of boronic acid were added and the reaction time was 8.5 hr.

our previous method[10] but better than that obtained with the reverse type of the Suzuki-Miyaura coupling reaction.[9] Using this procedure, molecules that could not be obtained by the previous method were prepared. The reaction with arylboronic acids bearing a hydroxyl or an amino group proceeded, as seen in entries 2, 3, 6, and 7. Increasing the amount of the palladium catalyst was not effective, as shown by the results of entries 6 and 7. Although 4-(3-nitrophenyl)-1*H*-1tritylpyrazole (**1e**) could not be synthesized in our previous work,[17] it was synthesized in this study albeit the low yield (entry 5). Other heteroarylboronic acids coupled with pyrazoles, as shown in entries 8-11. The Suzuki-Miyaura coupling reaction between *B*-(1*H*-1-tritylpyrazol-4-yl)boronic acid (**4**), which was prepared along Scheme 3, and 2-bromothiophene gave 4-(thiophen-2-yl)-1*H*-1-tritylpyrazole (**1g**) as shown in Scheme 4 in lower yield compared to entries 8, 9 in Table 1 under similar reaction conditions. Protection with trityl group at N-1 is necessary in this study since the desired coupled product could not been obtained under the same reaction condition when **2** was used as a coupling partner to phenylboronic acid. This result agreed to Fu's work[12] that the Suzuki-Miyaura coupling reaction between *B*-(1*H*-pyrazol-4-yl)boronic acid and chlorobenzene gave the desired product in lower yield (8%) than the corresponding reaction (64%) shown in eq.2 (Scheme 1).[10]

1) *n*-BuLi, Et$_2$O, –78°C, 30 min

2) B(OMe)$_3$

3) 1N HCl aq.

59%

Scheme 3. Synthesis of *B*-(1*H*-1-tritylpyrazol-4-yl)boronic acid **4**

Pd(OAc)$_2$ (5 mol%), PPh$_3$

THF / H$_2$O, K$_2$CO$_3$, 14.5 h

1g (31%)   **5** (52%)

1.2 eq.

Scheme 4. Alternative Suzuki-Miyaura cross coupling reaction to furnish **1g**

In summary, the Suzuki-Miyaura coupling reaction between 4-bromo-1*H*-1-tritylpyrazole and arylboronic acids was found to afford various kinds of 4-aryl-1*H*-pyrazoles. A direct preparation of 4-aryl-1*H*-pyrazoles with hydroxyl, nitro, or amino groups on the aryl ring resulted in relatively low yields. Nevertheless, this procedure is quite simple and practical as commercially available arylboronic acids can be used.

EXPERIMENTAL

IR spectra were obtained with a JEOL FT/IR-680 Plus spectrometer. HRMS was determined with a JEOL JMS-700 (2) mass spectrometer. NMR spectra were recorded at 27 ^{o}C on Varian UNITY INOVA-500 and Mercury-300 spectrometers in CDCl$_3$ with tetramethylsilane (TMS) as internal standard. Melting points were determined on a Yanagimoto micromelting point apparatus and are uncorrected. Liquid column chromatography was conducted over silica gel (Nacalai, silica gel 60, 70–230 mesh or 230–400 mesh). Analytical TLC was performed on precoated Merck glass plates (silica gel 60 F$_{254}$) and compounds were detected by dipping the plates in an ethanol solution of phosphomolybdic acid, followed by heating. Dry THF was distilled over sodium benzophenone ketyl under nitrogen atmosphere.

4-Bromo-1*H*-pyrazole (**2**)

To a solution of pyrazole (6.8 g, 100 mmol) in CH$_2$Cl$_2$ (120 mL) was added bromine (5.1 mL, 100 mmol) at 0 ^{o}C with stirring. After stirring overnight, the reaction mixture was treated with NaHSO$_4$ aq. and extracted with CH$_2$Cl$_2$. The organic layer was washed with brine, dried over MgSO$_4$, and filtered. The solvent as removed under reduced pressure to give a crude residue, which was purified by recrystallization to afford **2** (14.7 g, 100%). **2**: Colorless crystals; ^{1}H-NMR (300 MHz, CDCl$_3$): δ 6.97

(1H, s, pyrazole-H), 7.60 (1H, s, pyrazole-H).

4-Bromo-1*H*-1-tritylpyrazole (**3**)

To a solution of **2** (5.1 g, 35 mmol) in dry Et_2O (350 mL) with Et_3N (5.9 mL, 42 mmol) was added trityl chloride (12g, 42 mmol) under nitrogen atmosphere. After stirring for 1 hr at rt, the reaction mixture was quenched by the addition of water. The organic layer was washed with brine, dried over $MgSO_4$, and filtered. The solvent was removed under reduced pressure to give a crude residue, which was purified by recrystallization to afford **3** (12 g, 85%). **3**: Colorless crystals; ^{1}H-NMR (300 MHz, $CDCl_3$): δ 7.08−7.36 (15 H, m, Ph-H), 7.37 (1H, s, pyrazole-H), 7.61 (1H, s, pyrazole-H).

Synthesis of 4-aryl-1*H*-1-tritylpyrazoles (Table 1, Scheme 4)

General procedure: To a solution of **3** (389 mg, 1.0 mmol) in THF (5.0 mL) were added phenylboronic acid (293 mg, 2.4 mmol), $Pd(OAc)_2$ (225 mg, 0.05 mmol), triphenylphosphine (20 mg, 0.22 mmol), and K_2CO_3 (415 mg, 3.0 mmol). The reaction mixture was stirred under reflux overnight. The reaction mixture was quenched by the addition of dil. HCl aq. and extracted with EtOAc. The organic layer was washed with brine, dried over $MgSO_4$, and filtered. The solvent was removed under reduced pressure to give a crude residue, which was purified by column chromatography (hexane:EtOAc = 20:1) to afford **1a** (360 mg, 92%).

4-Phenyl-1*H*-1-tritylpyrazole[9] (**1a**): ^{1}H-NMR (300 MHz, $CDCl_3$): δ 7.94 (1H, s, pyrazole-H), 7.61 (1H, s, pyrazole-H), 7.14−7.45 (20H, m, Tr-H, Ph-H).

4-(4-Hydroxyphenyl)-1*H*-1-tritylpyrazole[8] (**1b**): ^{1}H-NMR (300 MHz, $CDCl_3$): δ 7.84 (1H, d, J = 0.8 Hz, pyrazole-H), 7.52 (1H, d, J = 0.8 Hz, pyrazole-H), 7.32−7.17 (15H, m, Tr-H), 7.25 (2H, d, J = 8.7 Hz, Ar-H), 6.74 (2H, d, J = 8.7 Hz, Ar-H), 5.04 (1H, brs, OH); ^{13}C-NMR (75 MHz, $CDCl_3$): δ 153.7, 142.6, 136.5, 129.8, 128.1, 127.4, 126.5, 124.9, 121.0, 115.4, 78.7 (lack of a carbon signal corresponding to the trityl-quaternary carbon, probably because of overlap with one of the chloroform signals); HRMS *m/z* calcd for $C_{28}H_{22}N_2O$ (M$^+$) 402.1732, found 402.1731.

4-(3-Hydroxyphenyl)-1*H*-1-tritylpyrazole (**1c**): Colorless crystals; mp 220−222 °C; IR (KBr) v_{max} 3272 (OH), 1610 (C=C), 1598 (C=C) cm^{-1}; ^{1}H-NMR (300 MHz, $CDCl_3$): δ 7.89 (1H, d, J = 0.7 Hz, pyrazole-H), 7.59 (1H, d, J = 0.7 Hz, pyrazole-H), 7.33−7.28 (9H, m, Tr-H), 7.21−7.16 (6H, m, Tr-H), 7.15 (1H, t, J = 8.8 Hz, Ar-H), 6.98 (1H, dt, J = 7.7, 1.5 Hz, Ar-H), 6.84 (1H, t, J = 2.4 Hz, Ar-H), 6.60 (1H, ddd, J = 8.1, 2.6, 0.9 Hz, Ar-H), 5.08 (1H, brs, OH); ^{13}C-NMR (75 MHz, $CDCl_3$): δ 155.4, 142.5, 136.8, 129.7, 129.6, 128.9, 127.4, 120.9, 117.6, 113.1, 112.1, 78.8 (lack of a carbon signal probably because of overlap with one of the chloroform signals); HRMS *m/z* calcd for $C_{28}H_{22}N_2O$ (M$^+$) 402.1732, found 402.1729.

4-(2-Tolyl)-1*H*-1-tritylpyrazole (**1d**): Colorless crystals; mp 100–103 °C; IR (KBr) ν_{max} 1602 (C=C), 1563 (C=C) cm^{-1}; ^{1}H-NMR (300 MHz, CDCl$_3$): δ 7.81 (1H, d, J = 0.7 Hz, pyrazole-H), 7.46 (1H, d, J = 0.7 Hz, pyrazole-H), 7.34–7.28 (10H, m, Tr-H, Tol-H), 7.25–7.1 (9H, m, Tr-H, Tol-H), 2.38 (3H, brs, CH$_3$); ^{13}C-NMR (75 MHz, CDCl$_3$): δ 143.2, 139.2, 135.2, 132.2, 131.3, 130.6, 130.2, 129.0, 127.9, 127.7, 126.7, 125.9, 120.7, 78.6, 21.2; MS (EI) *m/z* 400 (M$^+$), 243 (100%); HRMS *m/z* calcd for C$_{29}$H$_{24}$N$_2$ (M$^+$) 400.1940, found 400.1934.

4-(3-Nitrophenyl)-1*H*-1-tritylpyrazole (**1e**): Colorless crystals; mp 202–204 °C; IR (KBr) ν_{max} 1570 (C=C), 1528 (ArNO$_2$) cm^{-1}; ^{1}H-NMR (300 MHz, CDCl$_3$): δ 8.24 (1H, t, J = 2.2 Hz, 2'-H), 8.04 (1H, ddd, J = 8.0, 2.4, 1.1 Hz, 3'- or 6'-H), 8.00 (1H, d, J = 0.6 Hz, pyrazole-H), 7.75 (1H, br d, J = 8.0 Hz, 3'- or 6'-H), 7.74 (1H, d, J = 0.6 Hz, pyrazole-H), 7.49 (1H, t, J = 8.0 Hz, 2'-H), 7.38–7.32 (10H, m, Tr-H), 7.24–7.14 (5H, m, Tr-H); ^{13}C-NMR (75 MHz, CDCl$_3$): δ 148.7, 142.7, 137.3, 134.5, 131.3, 130.1, 129.7, 129.6, 128.0, 127.9, 120.9, 120.1, 119.6, 79.2; MS (EI) *m/z* 431 (M$^+$), 243 (100%); HRMS *m/z* calcd for C$_{28}$H$_{21}$N$_3$O$_2$ (M$^+$) 431.1634, found 431.1638.

4-(3-Aminophenyl)-1*H*-1-tritylpyrazole (**1f**): Colorless crystals; mp 155–157 °C; IR (KBr) ν_{max} 3380 (N-H), 1617 (C=C), 1588 (C=C) cm^{-1}; ^{1}H-NMR (300 MHz, CDCl$_3$): δ 7.89 (1H, d, J = 0.7 Hz, pyrazole-H), 7.57 (1H, d, J = 0.7 Hz, pyrazole-H), 7.38–7.31 (9H, m, Tr-H), 7.27–7.19 (6H, m, Tr-H), 7.09 (1H, t, J = 7.7 Hz, Ar-5H), 6.82 (1H, br d, J = 7.7, Hz, Ar-4H), 6.74 (1H, br s, Ar-2H), 6.52 (1H, dd, J = 7.7, 2.4 Hz, Ar-6H), 3.64 (2H, brs, -NH$_2$); ^{13}C-NMR (75 MHz, CDCl$_3$): δ 146.8, 143.1, 137.3, 133.5, 130.2, 129.7, 129.2, 127.8, 121.7, 116.0, 113.3, 112.1; MS (EI) *m/z* 401 (M$^+$), 243 (100%); HRMS *m/z* calcd for C$_{28}$H$_{23}$N$_3$ (M$^+$) 401.1892, found 401.1885.

4-(Thiophen-2-yl)-1*H*-1-tritylpyrazole[10] (**1g**): ^{1}H-NMR (200 MHz, CDCl$_3$): δ 7.84 (1H, d, J = 0.8 Hz, pyrazole-H), 7.55 (1H, d, J = 0.8 Hz, pyrazole-H), 7.33–7.28 (9H, m, Tr-H), 7.23–7.15 (6H, m, Tr-H), 7.08 (1H, dd, J = 5.0, 1.3 Hz, thienyl-5H), 6.99 (1H, dd, J = 3.6, 1.3 Hz, thienyl-3H), 6.94 (1H, dd, J = 5.0, 3.6 Hz, thienyl-4H).

4-(Thiophen-3-yl)-1*H*-1-tritylpyrazole (**1h**): Colorless crystals; mp 203–205 °C; IR (KBr) ν_{max} 1595 (C=C) cm^{-1}; ^{1}H-NMR (300 MHz, CDCl$_3$): δ 7.88 (1H, d, J = 0.7 Hz, pyrazole-H), 7.56 (1H, d, J = 0.7 Hz, pyrazole-H), 7.36–7.12 (9H, m, Ar-H); ^{13}C-NMR (75 MHz, CDCl$_3$): δ 143.1, 137.5, 130.1, 129.1, 127.9, 127.8, 127.8, 127.2, 126.1, 126.0, 118.2, 78.7; MS (EI) *m/z* 392 (M$^+$), 243 (100%); HRMS *m/z* calcd for C$_{26}$H$_{20}$N$_2$S (M$^+$) 392.1347, found 392.1345.

4-(Fur-2-yl)-1*H*-1-tritylpyrazole (**1i**): Colorless crystals; mp 114–118 °C; IR (KBr) ν_{max} 1610 (C=C), 1598 (C=C) cm^{-1}; ^{1}H-NMR (200 MHz, CDCl$_3$): δ 7.87 (1H, s, pyrazole-H), 7.61 (1H, s, pyrazole-H), 7.38–7.13 (16H, m, Tr-H, furyl-H), 6.40 (1H, dd, J = 3.6, 1.9 Hz, furyl-H), 6.31 (1H, d, J = 3.6 Hz, furyl-H); ^{13}C-NMR (75 MHz, CDCl$_3$): δ 146.8, 142.9, 140.6, 136.5, 130.1, 127.9, 127.8, 127.7, 127.2,

111.2, 103.7 (lack of a carbon signal probably because of overlap with one of the chloroform signals); MS (EI) m/z 376 (M$^+$), 243 (100%); HRMS m/z calcd for $C_{26}H_{20}N_2O$ (M$^+$) 376.1576, found 376.1579.

_B_-(1_H_-1-tritylpyrazol-4-yl)boronic acid (**4**) (Scheme 2)

To a suspension of **3** (19.6 g, 50 mmol) in Et$_2$O (250 mL) was added 1.6 M n-BuLi in hexane (35 mL, 55 mmol) at −78 ^{o}C under nitrogen atmosphere. After stirring for 30min, B(OMe)$_3$ (6.2 mL, 56mmol) was added. The reaction mixture was treated with 1N HCl aq., then extracted with EtOAc. The organic layer was separated, dried over MgSO$_4$, filtered and evaporated to give a crude residue, which was purified by column chromatography (eluent; MeOH:CH$_2$Cl$_2$= 100:1) to afford **4** (10.5g, 59%). **4**: Colorless crystals; mp 85−87 °C; IR (KBr) ν_{max} 3308 (OH), 1597 (C=C), 1536 (C=C) cm^{-1}; ^{1}H-NMR (200 MHz, CDCl$_3$): δ 7.92 (1H, s, pyrazole-H), 7.77 (1H, s, pyrazole-H), 7.34–7.28 (9H, m, Tr-H), 7.18–7.12 (6H, m, Tr-H); ^{13}C-NMR (75 MHz, CDCl$_3$): δ 145.1, 142.9, 138.7, 130.1, 130.0, 127.8, 127.6, 78.8; MS (FAB) m/z 310 ([M–BO$_2$H]$^+$), 309 ([M–B(OH)$_2$]$^+$), 243 (100%); HRFABMS m/z calcd for $C_{22}H_{18}N_2$ ([M–BO$_2$H]$^+$) 310. 1470, found 310.1475, m/z calcd for $C_{22}H_{17}N_2$ ([M–B(OH)$_2$]$^+$) 309.1392. 1470, found 309.1389.

REFERENCES

1. J. Elguero, P. Goya, N. Jagerovic, and A. M. S. Silva, _Targets in Heterocyclic Systems_, 2002, **6**, 52.

2. C. Lamberth, _Heterocycles_, 2007, **71**, 1467.

3. J.-M. Dogne, J. Hanson, C. Supuran, and D. Pratico, _Curr. Pharm. Des._, 2006, **12**, 971.

4. J. P. O'Connor and T. Lysz, _Drugs of Today_, 2008, **44**, 693.

5. J. H. M. Lange and C. G. Kruse, _Chemical Record_, 2008, **8**, 156.

6. J. Likforman, A. Brouard, C. Philippe, C. Bismuth, and E. J. Postaire, _Toxicol. Clinique et Experimentale_, 1987, **7**, 373.

7. N. De Brabander, M. Wojciechowski, K. De Decker, A. De Weerdt, and P. G. Jorens, _Euro. J. Pediatrics_, 2005, **164**, 158.

8. B. Stanovnik and J. Svete, _Science of Synthesis_, 2002, **12**, 15.

9. S. Fustero, A. Simon-Fuentes, and J. F. Sanz-Cervera, _Organic Preparations and Procedures_

International, 2009, **41**, 253.

10. T. Kanai, R. Komaki, T. Sato, S. Komeda, Y. Saito, and M. Chikuma, *Yakugaku Zasshi*, 2007, **127**, Suppl. 2, 51.

11. J. Elguero, C. Jaramillo, and C. Pardo, *Synthesis*, 1997, 563.

12. N. Kudo, M. Perseghini, and G. C. Fu, *Angew. Chem. Int. Ed.*, 2006, **45**, 1282.

13. D. N. Browne, M. D. Helm, A. Plant, and J. P. A. Harrity, *Angew. Chem. Int. Ed.*, 2007, **46**, 8656.

14. D. N. Browne, J. B. Taylor, A. Plant, and J. P. A. Harrity, *J. Org. Chem.*, 2009, **74**, 396.

15. D. N. Browne, J. F. Vivat, A. Plant, E. Gomez.-Bengoa, and J. P. A. Harrity, *J. Am. Chem. Soc.*, 2009, **131**, 7762.

16. R. S. Foster, J. Huang, J. F. Vivat, D. L. Browne, and J. P. A. Harrity, *Org. Biomol. Chem.*, 2009, **7**, 4052.

17. H. Ichikawa, Y. Ohno, Y. Usami, and M. Arimoto, *Heterocycles*, 2006, **68**, 2247.

18. A. Suzuki, *Handbook of Organopalladium Chemistry for Organic Synthesis* (Ed. by E. Negishi), Wiley Interscience, New York, 2002, chap. III.2.2.